SLC Family Transporters

  • Xiaodong LiuEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1141)


Solute carrier (SLC) family transporters utilize an electrochemical potential difference or an ion gradient generated by primary active transporters for transporting their substrates across biological membranes. These transporters are categorized as facilitated transporters or secondary active transporters. More than 300 SLC transporters have been identified. SLC transporters related to drug transport mainly include SLC21 gene subfamily (organic anion-transporting polypeptides, OATPs), SLC22A gene subfamily (organic anion transporters, OATs; organic cation transporters, OCTs; or organic cation/carnitine transporters, OCTNs), SLC15A gene subfamily (peptide transporters, PEPTs), and SLC47A gene subfamily (multidrug and toxin extrusion, MATEs). In general, OCTs transport organic cations, OATPs transport large and fairly hydrophobic organic anions, OATs transport the smaller and more hydrophilic organic anions, and PEPTs are responsible for the uptake of di-/tripeptides and peptide-like drugs. MATEs are responsible for efflux of organic cations. These transporters also transport some endogenous substances, indicating that the dysfunction of SLCs not only disrupts homeostasis but also largely impacts on the disposition of their substrate drugs. This chapter will discuss these SLC family transporters, with an emphasis on tissue distribution, substrate specificity, transporter physiology, and clinical significance.


Solute carrier Organic anion-transporting polypeptides Organic cation transporters Organic cation/carnitine transporters Organic anion transporters Peptide transporters Multidrug and toxin extrusion 



The project was in part supported by the National Natural Science Foundation of China (No. 81872930; 81573490) and “Double First-Class” University project (No. CPU2018GY22).


  1. Abe T, Unno M, Onogawa T, Tokui A, Kondo TN, Nakagomi R et al (2001) LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120:1689–1699CrossRefPubMedGoogle Scholar
  2. Agu R, Cowley E, Shao D, Mac Donald C, Kirkpatrick D, Renton K et al (2011) Proton-coupled oligopeptide transporter (POT) family expression in human nasal epithelium and their drug transport potential. Mol Pharm 8:664–672CrossRefPubMedGoogle Scholar
  3. Ahn SY, Nigam SK (2009) Toward a systems level understanding of organic anion and other multispecific drug transporters: a remote sensing and signaling hypothesis. Mol Pharmacol 76:481–490CrossRefPubMedPubMedCentralGoogle Scholar
  4. Ahn SY, Jamshidi N, Mo ML, Wu W, Eraly SA, Dnyanmote A et al (2011) Linkage of organic anion transporter-1 to metabolic pathways through integrated “omics”-driven network and functional analysis. J Biol Chem 286:31522–31531CrossRefPubMedPubMedCentralGoogle Scholar
  5. Akamine Y, Miura M, Komori H, Saito S, Kusuhara H, Tamai I et al (2014) Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers. Eur J Clin Pharmacol 70:1087–1095PubMedPubMedCentralGoogle Scholar
  6. Akamine Y, Miura M, Komori H, Tamai I, Ieiri I, Yasui-Furukori N et al (2015) The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion. Drug Metab Pharmacokinet 30:352–357PubMedPubMedCentralGoogle Scholar
  7. Akanuma S, Hosoya K, Ito S, Tachikawa M, Terasaki T, Ohtsuki S (2010) Involvement of multidrug resistance-associated protein 4 in efflux transport of prostaglandin E (2) across mouse blood-brain barrier and its inhibition by intravenous administration of cephalosporins. J Pharmacol Exp Ther 333:912–919CrossRefPubMedPubMedCentralGoogle Scholar
  8. Akanuma S, Uchida Y, Ohtsuki S, Tachikawa M, Terasaki T, Hosoya K (2011) Attenuation of prostaglandin E2 elimination across the mouse blood-brain barrier in lipopolysaccharide- induced inflammation and additive inhibitory effect of cefmetazole. Fluids Barriers CNS 8:24CrossRefPubMedPubMedCentralGoogle Scholar
  9. Aleksunes LM, Cui Y, Klaassen CD (2008) Prominent expression of xenobiotic efflux transporters in mouse extraembryonic fetal membranes compared with placenta. Drug Metab Dispos 36:1960–1970CrossRefPubMedPubMedCentralGoogle Scholar
  10. Allred AJ, Bowen CJ, Park JW, Peng B, Williams DD, Wire MB, Lee E (2011) Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. Br J Clin Pharmacol 72:321–329CrossRefPubMedPubMedCentralGoogle Scholar
  11. Amundsen R, Christensen H, Zabihyan B, Asberg A (2010) Cyclosporine A, but not tacrolimus, shows relevant inhibition of OATP1B1 mediated transport of atorvastatin. Drug Metabo Dispo 38:1499–1504CrossRefGoogle Scholar
  12. Andreev E, Koopman M, Arisz L (1999) A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med 246:247–252CrossRefPubMedGoogle Scholar
  13. Andreev E, Brosseau N, Carmona E, Mes-Masson AM, Ramotar D (2016) The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin. Sci Rep 6:20508CrossRefPubMedPubMedCentralGoogle Scholar
  14. Ayyadurai S, Charania MA, Xiao B, Viennois E, Merlin D (2013) PEPT1 expressed in immune cells has an important role in promoting the immune response during experimentally induced colitis. Lab Investig 9:888–899CrossRefGoogle Scholar
  15. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685–691CrossRefGoogle Scholar
  16. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ (2005) Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 78:154–167CrossRefGoogle Scholar
  17. Bacq A, Balasse L, Biala G, Guiard B, Gardier AM, Schinkel A et al (2012) Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response. Mol Psychiatry 17:926–939CrossRefPubMedGoogle Scholar
  18. Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D et al (2006) Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 318:521–529CrossRefPubMedGoogle Scholar
  19. Baganz NL, Horton RE, Calderon AS, Owens WA, Munn JL, Watts LT et al (2008) Organic cation transporter 3: Keeping the brake on extracellular serotonin in serotonin-transporter deficient mice. Proc Natl Acad Sci U S A 105:18976–18981CrossRefPubMedPubMedCentralGoogle Scholar
  20. Bailey DG (2010) Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol 70:645–655CrossRefPubMedPubMedCentralGoogle Scholar
  21. Bailey DG, Dresser GK, Leake BF, Kim RB (2007) Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 81:495–502CrossRefPubMedPubMedCentralGoogle Scholar
  22. Ballestero MR, Monte MJ, Briz O, Jimenez F, Gonzalez-San MF, Marin JJ (2006) Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem Pharmacol 72:729–738CrossRefPubMedGoogle Scholar
  23. Banerjee N, Allen C, Bendayan R (2012) Differential role of organic anion-transporting polypeptides in estrone-3-sulphate uptake by breast epithelial cells and breast cancer cells. J Pharmacol Exp Ther 342:510–519CrossRefPubMedGoogle Scholar
  24. Banerjee N, Fonge H, Mikhail A, Reilly RM, Bendayan R, Allen C et al (2013) Estrone-3-sulphate, a potential novel ligand for targeting breast cancers. PLoS ONE 8:e64069CrossRefPubMedPubMedCentralGoogle Scholar
  25. Banerjee N, Miller N, Allen C, Bendayan R (2014) Expression of membrane transporters and metabolic enzymes involved in estrone-3-sulphate disposition in human breast tumour tissues. Breast Cancer Res Treat 145:647–661CrossRefPubMedGoogle Scholar
  26. Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC (2009) Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 58:745–749CrossRefPubMedPubMedCentralGoogle Scholar
  27. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH (2010) Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics 20:38–44CrossRefPubMedGoogle Scholar
  28. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH (2011) OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics 12:79–82CrossRefPubMedGoogle Scholar
  29. Bednarczyk D, Boiselle C (2016) Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III. Xenobiotica 46:457–466CrossRefPubMedGoogle Scholar
  30. Ben Hassine I, Gharbi H, Soltani I, Teber M, Farrah A, Ben Hadj Othman H et al (2017) hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia. Cancer Chemother Pharmacol 79:737–745CrossRefPubMedGoogle Scholar
  31. Benet LZ (2009) The Drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm 6:1631–1643CrossRefPubMedPubMedCentralGoogle Scholar
  32. Bergmann OM, Kristjansson G, Jonasson JG, Björnsson ES (2012) Jaundice due to suspected statin hepatotoxicity: a case series. Dig Dis Sci 57:1959–1964CrossRefPubMedGoogle Scholar
  33. Bertoni A, Rastoldo A, Sarasso C, Di Vito C, Sampietro S, Nalin M et al (2012) Dehydroepiandrosterone-sulfate inhibits thrombin-induced platelet aggregation. Steroids 77:260–268CrossRefPubMedGoogle Scholar
  34. Blache D, Becchi M, Davignon J (1995) Occurrence and biological effects of cholesteryl sulfate on blood platelets. Biochim Biophys Acta 1259:291–296CrossRefPubMedGoogle Scholar
  35. Boxberger KH, Hagenbuch B, Lampe JN (2014) Common drugs inhibit human organic cation transporter 1 (OCT1)-mediated neurotransmitter uptake. Drug Metab Dispos 42:990–995CrossRefPubMedPubMedCentralGoogle Scholar
  36. Brandoni A, Torres AM (2015) Altered renal expression of relevant clinical drug transporters in different models of acute uremia in rats. Role of urea levels. Cell Physiol Biochem 36:907–916CrossRefPubMedGoogle Scholar
  37. Brandsch M (2013) Drug transport via the intestinal peptide transporter PEPT1. Curr Opin Pharmacol 13:881–887CrossRefGoogle Scholar
  38. Brennan BJ, Moreira SA, Morcos PN, Navarro MT, Asthappan J, Goelzer P et al (2013) Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin. Clin Pharmacokinet 52:805–813CrossRefPubMedPubMedCentralGoogle Scholar
  39. Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK et al (2011) Differential effect of the rs 4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 12:233–237CrossRefPubMedGoogle Scholar
  40. Bruyn TD, Fattah S, Stieger B, Augustijns P, Annaert P (2011) Sodium Fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3. J Pharm Sci 100:5018–5030CrossRefPubMedGoogle Scholar
  41. Bugnicourt JM, Godefroy O, Chillon JM, Choukroun G, Massy ZA (2013) Cognitive disorders and dementia in CKD: the neglected kidney-brain axis. J Am Soc Nephrol 24:353–363CrossRefGoogle Scholar
  42. Burckhardt G (2012) Drug transport by organic anion transporters (OATs). Pharmacol Ther 136:106–130CrossRefPubMedGoogle Scholar
  43. Busti AJ, Bain AM, Hall RG 2nd, Bedimo RG, Leff RD, Meek C et al (2008) Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 51:605–610CrossRefPubMedGoogle Scholar
  44. Buxhofer-Ausch V, Sheikh M, Ausch C, Zotter S, Bauer H, Mollik M et al (2018) Abundance of the organic anion-transporting polypeptide OATP4A1 in early-stage colorectal cancer patients: association with disease relapse. Appl Immunohistochem Mol Morphol 2018.
  45. Buyse M, Tsocas A, Walker F, Merlin D, Bado A (2002) PEPT1-mediated fMLP transport induces intestinal inflammation in vivo. Am J Physiol Cell Physiol 283:C1795–C1800CrossRefPubMedGoogle Scholar
  46. Caetano-Pinto P, Jamalpoor A, Ham J, Goumenou A, Mommersteeg M, Pijnenburg D et al (2017) Cetuximab prevents methotrexate-induced cytotoxicity in vitro through epidermal growth factor dependent regulation of renal drug transporters. Mol Pharm 14:2147–2157CrossRefPubMedPubMedCentralGoogle Scholar
  47. Cao F, Gao Y, Wang M, Fang L, Ping Q (2013) Propylene glycol-linked amino acid/dipeptide diester prodrugs of oleanolic acid for PEPT1-mediated transport: synthesis, intestinal permeability, and pharmacokinetics. Mol Pharm 10:1378–1387CrossRefPubMedGoogle Scholar
  48. Carr DF, O’Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G et al (2013) SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther 94:695–701CrossRefPubMedPubMedCentralGoogle Scholar
  49. Chan T, Zhu L, Madigan MC, Wang K, Shen W, Gillies MC et al (2015) Human organic anion transporting polypeptide 1A2 (OATP1A2) mediates cellular uptake of all-trans-retinol in human retinal pigmented epithelial cells. Brit J Pharmacol 172:2343–2353CrossRefGoogle Scholar
  50. Chang JH, Plise E, Cheong J, Ho Q, Lin M (2013) Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia. Mol Pharm 10:3067–3075CrossRefPubMedGoogle Scholar
  51. Charrier L, Merlin D (2006) The oligopeptide transporter hPEPT1: gateway to the innate immune response. Lab Investig 86:538–546CrossRefPubMedGoogle Scholar
  52. Charrier L, Driss A, Yan Y, Nduati V, Klapproth JM, Sitaraman SV, Merlin D (2006) hPEPT1 mediates bacterial tripeptide fMLP uptake in human monocytes. Lab Investig 86:490–503CrossRefPubMedGoogle Scholar
  53. Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK et al (2009a) Effect of genetic variation in the organic cation transporter 2, OCT2, on the renal elimination of metformin. Pharmacogenet Genomics 19:497–504CrossRefPubMedPubMedCentralGoogle Scholar
  54. Chen Y, Teranishi K, Li S, Yee SW, Hesselson S, Stryke D et al (2009b) Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J 9:127–136CrossRefPubMedPubMedCentralGoogle Scholar
  55. Chen Y, Zhang W, Huang WH, Tan ZR, Wang YC, Huang X et al (2013) Effect of a single-dose rifampin on the pharmacokinetic pitavastatin in healthy volunteers. Eur J Clin Pharmacol 69:1933–1938CrossRefPubMedPubMedCentralGoogle Scholar
  56. Chen L, Shu Y, Liang X, Chen EC, Yee SW, Zur AA et al (2014) OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A 111:9983–9988CrossRefPubMedPubMedCentralGoogle Scholar
  57. Chen R, Wang J, Tang S, Zhang Y, Lv X, Wu S et al (2015a) Association of polymorphisms in drug transporter genes (SLCO1B1 and SLC10A1) and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort. Tuberculosis (Edinb) 95:68–74CrossRefGoogle Scholar
  58. Chen L, Yee SW, Giacomini KM (2015b) OCT1 in hepatic steatosis and thiamine disposition. Cell Cycle 14:283–284CrossRefPubMedPubMedCentralGoogle Scholar
  59. Cheng Y, Vapurcuyan A, Shahidullah M, Aleksunes LM, Pelis RM (2012) Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. Drug Metab Dispos 40:617–624CrossRefPubMedGoogle Scholar
  60. Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR (2000) Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72:23–27CrossRefPubMedGoogle Scholar
  61. Cho SK, Yoon JS, Lee MG, Lee DH, Lim LA, Park K et al (2011) Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther 89:416–421CrossRefPubMedPubMedCentralGoogle Scholar
  62. Cho AK, Kim CO, Park ES, Chung JY (2014) Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers. Br J Clin Pharmacol 78:1426–1432CrossRefPubMedPubMedCentralGoogle Scholar
  63. Christensen MM, Pedersen RS, Stage TB, Brasch-Andersen C, Nielsen F, Damkier P et al (2013) A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics 23:526–534CrossRefPubMedGoogle Scholar
  64. Chung JY, Cho SK, Kim TH, Kim KH, Jang GH, Kim CO et al (2013) Functional characterization of MATE2-K genetic variants and their effects on metformin pharmacokinetics. Pharmacogenet Genomics 23:365–373CrossRefPubMedGoogle Scholar
  65. Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B et al (2010) Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176:1169–1180CrossRefPubMedPubMedCentralGoogle Scholar
  66. Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pavenstädt H et al (2012) Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res 18:1101–1108CrossRefPubMedPubMedCentralGoogle Scholar
  67. Clarke JD, Hardwick RN, Lake AD, Canet MJ, Cherrington NJ (2014) Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression. J Pharmacol Exp Ther 348:452–458CrossRefPubMedPubMedCentralGoogle Scholar
  68. Corcoran GB, Salazar DE (1989) Obesity as a risk factor in drug-induced organ injury. IV. Increased gentamicin nephrotoxicity in the obese overfed rat. J Pharmacol Exp Ther 248:17–22PubMedGoogle Scholar
  69. Corcoran GB, Salazar DE, Schentag JJ (1988) Excessive aminoglycoside nephrotoxicity in obese patients. Am J Med 85:279CrossRefPubMedGoogle Scholar
  70. Couroussé T, Gautron G (2015) Role of organic cation transporters (OCTs) in the brain. Pharmacol Ther 146:94–103CrossRefPubMedPubMedCentralGoogle Scholar
  71. Couroussé T, Bacq A, Belzung C, Guiard B, Balasse L, Louis F et al (2015) Brain organic cation transporter 2 controls response and vulnerability to stress and GSK3β signaling. Mol Psychiatry 20:889–900CrossRefPubMedGoogle Scholar
  72. Cropp CD, Komori T, Shima JE, Urban TJ, Yee SW, More SS et al (2008) Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol 73:1151–1158CrossRefPubMedPubMedCentralGoogle Scholar
  73. Csanaky IL, Lu H, Zhang Y, Ogura K, Choudhuri S, Klaassen CD (2011) Organic anion–transporting polypeptide 1b2 (Oatp 1b2) is important for the hepatic uptake of unconjugated bile acids: studies in Oatp 1b2-null mice. Hepatology 53:272–281CrossRefPubMedGoogle Scholar
  74. da Cunha Vasconcelos F, Mauricio Scheiner MA, Moellman-Coelho A, Mencalha AL, Renault IZ, Rumjanek VM et al (2016) Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice. Leuk Res 51:3–10CrossRefPubMedGoogle Scholar
  75. Dalmasso G, Nguyen HT, Charrier-Hisamuddin L, Yan Y, Laroui H, Demoulin B et al (2010) PEPT1 mediates transport of the proinflammatory bacterial tripeptide L-Ala-{gamma}- D-Glu-meso-DAP in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 299:G687–G696CrossRefPubMedPubMedCentralGoogle Scholar
  76. Dalmasso G, Nguyen HT, Ingersoll SA, Ayyadurai S, Laroui H, Charania MA et al (2011) The PEPT1-NOD2 signaling pathway aggravates induced colitis in mice. Gastroenterology 141:1334–1345CrossRefPubMedPubMedCentralGoogle Scholar
  77. Damman K, Perez AC, Anand IS, Komajda M, McKelvie RS, Zile MR et al (2014) Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. J Am Coll Cardiol 64:1106–1113CrossRefPubMedGoogle Scholar
  78. Damman K, Solomon SD, Pfeffer MA, Swedberg K, Yusuf S, Young JB et al (2016) Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. Eur J Heart Fail 8:1508–1517CrossRefGoogle Scholar
  79. de Graan AJM, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE et al (2012) Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 18:4433–4440CrossRefPubMedPubMedCentralGoogle Scholar
  80. de Kanter CT, Keuter M, van der Lee MJ, Koopmans PP, Burger DM (2011) Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir. Antivir Ther 16:435–437CrossRefPubMedGoogle Scholar
  81. de Lima LT, Vivona D, Bueno CT, Hirata RD, Hirata MH, Luchessi AD et al (2014) Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Med Oncol 31:851CrossRefPubMedGoogle Scholar
  82. Deguchi T, Isozaki K, Yousuke K, Terasaki T, Otagiri M (2006) Involvement of organic anion transporters in the efflux of uremic toxins across the blood–brain barrier. J Neurochem 96:1051–1059CrossRefPubMedGoogle Scholar
  83. Dingemanse J, van Giersbergen PL, Patat A, Nilsson PN (2010) Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antivir Ther 15:157–163CrossRefPubMedGoogle Scholar
  84. Donovan MD, O’Brien FE, Boylan GB, Cryan JF, Griffin BT (2014) The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat. J Pharm Pharmacol 67:501–510CrossRefPubMedGoogle Scholar
  85. Donovan MD, Schellekens H, Boylan GB, Cryan JF, Griffin BT (2016) In vitro bidirectional permeability studies identify pharmacokinetic limitations of NKCC1 inhibitor bumetanide. Eur J Pharmacol 770:117–125CrossRefPubMedGoogle Scholar
  86. Duan H, Hu T, Foti RS, Pan Y, Swaan PW, Wang J (2015) Potent and selective inhibition of plasma membrane monoamine transporter by HIV protease inhibitors. Drug Metab Dispos 43:1773–1780CrossRefPubMedPubMedCentralGoogle Scholar
  87. Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CAN, Pearson ER (2015) Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: A GoDARTS study. Diabetes 64:1786–1793CrossRefPubMedGoogle Scholar
  88. Engler JR, Frede A, Saunders VA, Zannettino AC, Hughes TP, White DL (2010) Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 24:765–770CrossRefPubMedGoogle Scholar
  89. Engler JR, Zannettino AC, Bailey CG, Rasko JE, Hughes TP, White DL (2011) OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica 96:213–220CrossRefPubMedGoogle Scholar
  90. Enomoto A, Niwa T (2007) Roles of organic anion transporters in the progression of chronic renal failure. Ther Apher Dial 11(Suppl 1):S27–S31CrossRefPubMedGoogle Scholar
  91. Enomoto A, Wempe MF, Tsuchida H, Shin HJ, Cha SH, Anzai N et al (2002) Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J Biol Chem 277:36262–36271CrossRefPubMedGoogle Scholar
  92. Eraly SA, Vallon V, Vaughn DA, Gangoiti JA, Richter K, Nagle M et al (2006) Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J Biol Chem 281:5072–5083CrossRefPubMedGoogle Scholar
  93. Erhardt S, Olsson SK, Engberg G (2009) Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 23:91–101CrossRefPubMedGoogle Scholar
  94. Fan Y, Wei F, Lang Y, Wang S (2015) Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis. J Hypertens 33:681–688CrossRefPubMedGoogle Scholar
  95. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin induced nephrotoxicity. Clin Pharmacol Ther 86:396–402CrossRefPubMedPubMedCentralGoogle Scholar
  96. Fork C, Bauer T, Golz S, Geerts A, Weiland J, Del Turco D et al (2011) OAT2 catalyses efflux of glutamate and uptake of orotic acid. Biochem J 436:305–312CrossRefPubMedGoogle Scholar
  97. Franke RM, Kosloske AM, Lancaster CS, Filipski KK, C H, Zolk O et al (2010) Influence of Oct 1/Oct 2-deficiency on cisplatin-induced changes in urinary N-Acetyl-β-D-glucosaminidase. Clin Cancer Res 16:4198–4206CrossRefPubMedPubMedCentralGoogle Scholar
  98. Fujita D, Saito Y, Nakanishi T, Tamai I (2016) Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to gastrointestinal toxicity of anticancer drug SN-38, active metabolite of irinotecan hydrochloride. Drug Metab Dispos 44:1–7CrossRefPubMedGoogle Scholar
  99. Furberg CD, Pitt B (2001) Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2:205–207CrossRefPubMedPubMedCentralGoogle Scholar
  100. Furihata T, Matsumoto S, Fu Z, Tsubota A, Sun Y, Matsumoto S et al (2014) Different interaction profiles of directing-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother 58:4555–4564CrossRefPubMedPubMedCentralGoogle Scholar
  101. Futterman LG, Lemberg L (2004) Statin pleiotropy: fact or fiction? Am J Crit Care 13:244–249PubMedGoogle Scholar
  102. Gai Z, Visentin M, Hiller C, Krajnc E, Li T, Zhen J et al (2016) Organic cation transporter 2 overexpression may confer an increased risk of gentamicin-induced nephrotoxicity. Antimicrob Agents Chemother 60:5573–5580CrossRefPubMedPubMedCentralGoogle Scholar
  103. Gao B, Vavricka SR, Meier PJ, Stieger B (2015) Differential cellular expression of organic anion transporting peptides OATP1A2 and OATP2B1 in the human retina and brain: implications for carrier-mediated transport of neuropeptides and neurosteriods in the CNS. Pflugers Arch 467:1481–1493CrossRefGoogle Scholar
  104. Gasser PJ, Lowry CA, Orchinik M (2006) Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: potential role for organic cation transporter 3 in stress-induced modulation of monoaminergic neurotransmission. J Neurosci 26:8758–8766CrossRefPubMedPubMedCentralGoogle Scholar
  105. Gasser PJ, Hurley MM, Chan J, Pickel VM (2017) Organic cation transporter 3 (OCT3) is localized to intracellular and surface membranes in select glial and neuronal cells within the basolateral amygdaloid complex of both rats and mice. Brain Struct Funct 222:1913–1928CrossRefPubMedGoogle Scholar
  106. Geier A, Macias RIR, Bettinger D, Weiss J, Bantel H, Jahn D et al (2017) The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. Oncotarget 8:15846–15857CrossRefPubMedPubMedCentralGoogle Scholar
  107. Gilligan LC, Gondal A, Tang V, Hussain MT, Arvaniti A, Hewitt AM et al (2017) Estrone Sulfate transport and steroid sulfatase activity in colorectal cancer: implications for hormone replacement therapy. Front Pharmacol 8:103CrossRefPubMedPubMedCentralGoogle Scholar
  108. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS (2007) Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 81:363–370CrossRefGoogle Scholar
  109. Gong IY, Kim RB (2013) Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet 28:4–18CrossRefPubMedGoogle Scholar
  110. Gong Y, Wu X, Wang T, Zhao J, Liu X, Yao Z et al (2017) Targeting PEPT1: a novel strategy to improve the antitumor efficacy of doxorubicin in human hepatocellular carcinoma therapy. Oncotarget 8:40454–40468PubMedPubMedCentralGoogle Scholar
  111. Grimm D, Lieb J, Weyer V, Vollmar J, Darstein F, Lautem A et al (2016) Organic cation transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. BMC Cancer 16:94CrossRefPubMedPubMedCentralGoogle Scholar
  112. Grottker J, Rosenberger A, Burckhardt G, Hagos Y (2011) Interaction of human multidrug and toxin extrusion 1 (MATE1) transporter with antineoplastic agents. Drug Metabol Drug Interact 26:181–189CrossRefPubMedPubMedCentralGoogle Scholar
  113. Grube M, Köck K, Oswald S, Draber K, Meissner K, Eckel L et al (2006) Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 80:607–620CrossRefPubMedPubMedCentralGoogle Scholar
  114. Grube M, Reuther S, Meyer zu Schwabedissen H, Köck K, Draber K, Ritter CA et al (2007) Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta. Drug Metab Dispos 35:30–35CrossRefPubMedPubMedCentralGoogle Scholar
  115. Grün B, Kiessling MK, Burhenne J, Riedel KD, Weiss J, Rauch G et al (2013) Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. Brit J Clin Pharmacol 76:787–796CrossRefGoogle Scholar
  116. Gui C, Hagenbuch B (2009) Role of transmembrane domain 10 for the function of organic anion transporting polypeptide 1B1. Protein Sci 18:2298–2306CrossRefPubMedPubMedCentralGoogle Scholar
  117. Gupta D, Gupta SV, Dahan A, Tsume Y, Hilfinger J, Lee KD et al (2013) Increasing Oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Mol Pharm 10:512–522CrossRefPubMedPubMedCentralGoogle Scholar
  118. Hagenbuch B, Meier PJ (2003) The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609:1–18CrossRefGoogle Scholar
  119. Hagenbuch B, Meier PJ (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653–665CrossRefPubMedPubMedCentralGoogle Scholar
  120. Hagenbuch B, Stieger B (2013) The SLCO (former SLC21) Superfamily of transporters. Mol Asp Med 34:396–412CrossRefGoogle Scholar
  121. Hagiya Y, Endo Y, Yonemura Y, Takahashi K, Ishizuka M, Abe F et al (2012) Pivotal roles of peptide transporter PEPT1 and ATP-binding cassette (ABC) transporter ABCG2 in 5-aminolevulinic acid (ALA)-based photocytotoxicity of gastric cancer cells in vitro. Photodiagn Photodyn Ther 9:204–214CrossRefGoogle Scholar
  122. Hagiya Y, Fukuhara H, Matsumoto K, Endo Y, Nakajima M, Tanaka T et al (2013) Expression levels of PEPT1 and ABCG2 play key roles in 5-aminolevulinic acid (ALA)-induced tumor-specific protoporphyrin IX (PpIX) accumulation in bladder cancer. Photodiagn Photodyn Ther 10:288–295CrossRefGoogle Scholar
  123. Hagos Y, Wolff NA (2010) Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity. Toxins 2:2055–2082CrossRefPubMedPubMedCentralGoogle Scholar
  124. Hagos Y, Hundertmark P, Shnitsar V, Marada VV, Wulf G, Burckhardt G (2015) Renal human organic anion transporter 3 increases the susceptibility of lymphoma cells to bendamustine uptake. Am J Physiol Renal Physiol 308:F330–F338CrossRefGoogle Scholar
  125. Hamada T, Mizuta E, Kondo T, Hirai M, Yamada K, Kato M et al (2010) Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients. Arzneimittelforschung 60:71–75PubMedGoogle Scholar
  126. Hamre K, Tharp R, Poon K, Xiong X, Smeyne RJ (1999) Differential strain susceptibility following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res 828:91–103CrossRefGoogle Scholar
  127. Han YH, Busler D, Hong Y, Tian Y, Chen C, Rodrigues AD (2010) Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters. Drug Metab Dispos 38:1072–1082CrossRefGoogle Scholar
  128. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D et al (2010) HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 20:112–120CrossRefPubMedPubMedCentralGoogle Scholar
  129. Hashimoto Y, Tatsumi S, Takeda R, Naka A, Ogane N et al (2014) Expression of organic anion-transporting polypeptide 1A2 and organic cation transporter 6 as a predictor of pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. Breast Cancer Res Treat 145:101–111CrossRefPubMedGoogle Scholar
  130. Hays A, Apte U, Hagenbuch B (2013) Organic anion transporting polypeptides expressed in pancreatic cancer may serve as potential diagnostic markers and therapeutic targets for early stage adenocarcinomas. Pharm Res 30:2260–2269CrossRefPubMedPubMedCentralGoogle Scholar
  131. He R, Zhang D, Lu W, Zheng T, Wan L, Liu F et al (2015) SLC47A1 gene rs 2289669 G > A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients. Diabetes Res Clin Pract 109:57–63CrossRefPubMedPubMedCentralGoogle Scholar
  132. Heise M, Lautem A, Knapstein J, Schattenberg JM, Hoppe-Lotichius M, Foltys D et al (2012) Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer 12:109CrossRefPubMedPubMedCentralGoogle Scholar
  133. Henjakovic M, Hagos Y, Krick W, Burckhardt G, Burckhardt BC (2015) Human organic anion transporter 2 is distinct from organic anion transporters 1 and 3 with respect to transport function. Am J Physiol Renal Physiol 309:F843–F851CrossRefPubMedPubMedCentralGoogle Scholar
  134. Herraez E, Lozano E, Macias RIR, Vaquero J, Bujanda L, Banales JM et al (2013) Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology 58:1065–1073CrossRefPubMedPubMedCentralGoogle Scholar
  135. Hill JE, Gasser PJ (2013) Organic cation transporter 3 is densely expressed in the intercalated cell groups of the amygdala: anatomical evidence for a stress hormone-sensitive dopamine clearance system. J Chem Neuroanat 52:36–43CrossRefPubMedPubMedCentralGoogle Scholar
  136. Hirano M, Maeda K, Shitara Y, Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139–146CrossRefPubMedPubMedCentralGoogle Scholar
  137. Ho ES, Lin DC, Mendel DB, Cihlar T (2000) Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 11:383–393PubMedPubMedCentralGoogle Scholar
  138. Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG et al (2007) Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics 17:647–656CrossRefPubMedPubMedCentralGoogle Scholar
  139. Horton RE, Apple DM, Owens WA, Baganz NL, Cano S, Mitchell NC et al (2013) Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: uncovering novel targets to treat depression. J Neurosci 33:10534–10543CrossRefPubMedPubMedCentralGoogle Scholar
  140. Hosoya K, Tachikawa M (2011) Roles of organic anion/cation transporters at the blood–brain and blood–cerebrospinal fluid barriers involving uremic toxins. Clin Exp Nephrol 15:478–485CrossRefGoogle Scholar
  141. Hosoya K, Makihara A, Tsujikawa Y, Yoneyama D, Mori S, Terasaki T et al (2009) Roles of inner blood-retinal barrier organic anion transporter 3 in the vitreous/retina-to-blood efflux transport of p-aminohippuric acid, benzylpenicillin, and 6-mercaptopurine. J Pharmacol Exp Ther 329:87–93CrossRefGoogle Scholar
  142. Hou Q, Li S, Li L, Li Y, Sun X, Tian H (2015a) Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk. A meta-analysis of case–control studies. Medicine e1268:94Google Scholar
  143. Hou W, Zhang D, Lu W, Zheng T, Wan L, Li Q et al (2015b) Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients. Mol Diagn Ther 19:25–33CrossRefPubMedPubMedCentralGoogle Scholar
  144. Hsueh CH, Yoshida K, Zhao P, Meyer TW, Zhang L et al (2016) Identification and quantitative assessment of uremic solutes as inhibitors of renal organic anion transporters, OAT1 and OAT3. Mol Pharm 13:3130–3140CrossRefPubMedPubMedCentralGoogle Scholar
  145. Hu ZY (2013) Disposition pathway-dependent approach for predicting organic anion-transporting polypeptide-mediated drug-drug interactions. Clin Pharmacokinet 52:433–441CrossRefPubMedPubMedCentralGoogle Scholar
  146. Hu Y, Smith DE (2016) Species differences in the pharmacokinetics of cefadroxil as determined in wild type and humanized PEPT1 mice. Biochem Pharmacol 107:81–90CrossRefPubMedPubMedCentralGoogle Scholar
  147. Hu Y, Shen H, Keep RF, Smith DE (2007) Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity. J Neurochem 103:2058–2065CrossRefPubMedPubMedCentralGoogle Scholar
  148. Hu Y, Smith DE, Ma K, Jappar D, Thomas W, Hillgren KM (2008) Targeted disruption of peptide transporter PEPT1 Gene in mice significantly reduces dipeptide absorption in intestine. Mol Pharm 5:1122–1130CrossRefPubMedPubMedCentralGoogle Scholar
  149. Hu S, Mathijssen RH, de Bruijn P, Baker SD, Sparreboom A (2014a) Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer 110:894–898CrossRefPubMedPubMedCentralGoogle Scholar
  150. Hu Y, Xie Y, Keep RF, Smith DE (2014b) Divergent developmental expression and function of the proton-coupled oligopeptide transporters PEPT2 and PHT1 in regional brain slices of mouse and rat. J Neurochem 129:955–965CrossRefPubMedPubMedCentralGoogle Scholar
  151. Huang J, Li N, Hong W, Zhan K, Yu X, Huang H et al (2013) Conserved tryptophan residues within putative transmembrane domain 6 affect transport function of organic anion transporting polypeptide 1B1. Mol Pharmacol 84:521–527CrossRefPubMedPubMedCentralGoogle Scholar
  152. Hubeny A, Keiser M, Oswald S, Jedlitschky G, Kroemer HK, Siegmund W et al (2016) Expression of organic anion transporting polypeptide 1A2 in red blood cells and its potential impact on antimalarial therapy. Drug Metab Dispos 44:1562–1568CrossRefPubMedPubMedCentralGoogle Scholar
  153. Huber RD, Gao B, Sidler Pfändler MA, Zhang-Fu W, Leuthold S, Hagenbuch B et al (2007) Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am J Physiol Cell Physiol 292:C795–C806CrossRefPubMedPubMedCentralGoogle Scholar
  154. Hucke A, Ciarimboli G (2016) The Role of Transporters in the toxicity of chemotherapeutic drugs: focus on transporters for organic cations. J Clin Pharmacol 56(Suppl 7):S157–S172CrossRefPubMedPubMedCentralGoogle Scholar
  155. Hussner J, Begunk R, Boettcher K, Gliesche DG, Prestin KP, Meyer zu Schwabedissen HE et al (2015) Expression of OATP2B1 as determinant of drug effects in the microcompartment of the coronary artery. Vasc Pharmacol 72:25–34CrossRefGoogle Scholar
  156. Imamura Y, Murayama N, Okudaira N, Kurihara A, Okazaki O, Izumi T et al (2011) Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther 89:81–88CrossRefPubMedPubMedCentralGoogle Scholar
  157. Imamura Y, Tsuruya Y, Damme K, Heer D, Kumagai Y, Maeda K et al (2014) 6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. Drug Metab Dispos 42:685–694CrossRefPubMedPubMedCentralGoogle Scholar
  158. Ingersoll SA, Ayyadurai S, Charania MA, Laroui H, Yan Y, Merlin D (2012) The role and pathophysiological relevance of membrane transporter Pep T1 in intestinal inflammation and inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 302:G484–G492CrossRefGoogle Scholar
  159. Ingraham L, Li M, Renfro JL, Parker S, Vapurcuyan A, Hanna I et al (2014) A plasma concentration of α-ketoglutarate influences the kinetic interaction of ligands with organic anion transporter 1. Mol Pharmacol 86:86–95CrossRefPubMedPubMedCentralGoogle Scholar
  160. Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T et al (2006) Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34:1109–1115CrossRefPubMedPubMedCentralGoogle Scholar
  161. Ito S, Kusuhara H, Kuroiwa Y, Wu C, Moriyama Y, Inoue K et al (2010) Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 333:341–350CrossRefPubMedPubMedCentralGoogle Scholar
  162. Ito S, Kusuhara H, Kumagai Y, Moriyama Y, Inoue K, Kondo T et al (2012a) N-methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K). Clin Pharmacol Ther 92:635–641CrossRefPubMedPubMedCentralGoogle Scholar
  163. Ito S, Kusuhara H, Yokochi M, J Toyoshima J, Inoue K, Yuasa H et al (2012b) Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 340:393–403CrossRefPubMedPubMedCentralGoogle Scholar
  164. Iusuf D, Hendrikx JJMA, van Esch A, van de Steeg E, Els Wagenaar E, Rosing H et al (2015) Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel. Int J Cancer 136:225–233CrossRefPubMedPubMedCentralGoogle Scholar
  165. Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I (2007) Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 320:211–217CrossRefPubMedPubMedCentralGoogle Scholar
  166. Iwata K, Aizawa K, Kamitsu S, Jingami S, Fukunaga E, Yoshida M et al (2012) Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin Exp Nephrol 6:843–851CrossRefGoogle Scholar
  167. Izumi S, Nozaki Y, Komori T, Maeda K, Takenaka Q, Kusano K et al (2013) Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17β-glucuronide, estrone-3-sulfate, and sulfobromophthaleins. Drug Metab Dispos 41:1859–1866CrossRefPubMedPubMedCentralGoogle Scholar
  168. Izumi S, Nozaki Y, Maeda K, Komori T, Takenaka O, Kusuhara H et al (2015) Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1b1 inhibition profiles for the prediction of drug-drug interactions. Drug Metab Dispos 43:235–247CrossRefPubMedPubMedCentralGoogle Scholar
  169. Jacobson TA (2004) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P 450 inhibitors. Am J Cardiol 94:1140–1146CrossRefPubMedPubMedCentralGoogle Scholar
  170. Jappar D, Wu SP, Hu Y, Smith DE (2010) Significance and regional dependency of peptide transporter (PEPT) 1 in the intestinal permeability of glycylsarcosine: in situ single-pass perfusion studies in wild-type and pept 1 knockout mice. Drug Metab Dispos 38:1740–1746CrossRefPubMedPubMedCentralGoogle Scholar
  171. Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao C, Madhusudan Rao Y (2002) Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers. Drug Metabol Drug Interact 19:41–48CrossRefPubMedPubMedCentralGoogle Scholar
  172. Jeon H, Jang IJ, Lee SH, Ohashi K, Kotegawa T, Ieiri I et al (2012) Apple juice greatly reduces systemic exposure to atenolol. Br J Clin Pharmacol 75:172–179CrossRefGoogle Scholar
  173. Jin HE, Hong SS, Choi MK, Maeng HJ, Kim DD, Chung SJ et al (2009) Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct 1 in rats with ethynylestradiol-induced cholestasis. Pharm Res 26:549–559CrossRefPubMedPubMedCentralGoogle Scholar
  174. Jonker JW, Schinkel AH (2004) Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 308:2–9CrossRefPubMedPubMedCentralGoogle Scholar
  175. Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK et al (2002) Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci 70:1861–1874CrossRefPubMedGoogle Scholar
  176. Jung N, Lehmann C, Rubbert A, Schömig E, Fätkenheuer G, Hartmann P et al (2013) Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients. Infection 41:379–385CrossRefPubMedGoogle Scholar
  177. Kagawa T, Oka A, Kobayashi Y, Hiasa Y, Kitamura T, Sakugawa H et al (2015) Recessive inheritance of population-specific intronic LINE-1 insertion causes a rotor syndrome phenotype. Hum Mutat 36:327–232CrossRefPubMedGoogle Scholar
  178. Kajiwara M, Terada T, Ogasawara K, Iwano J, Katsura T, Fukatsu A et al (2009) Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. Hum Genet 54:40–66CrossRefGoogle Scholar
  179. Kajiwara M, Ban T, Matsubara K, Nakanishi Y, Masuda S (2016) Urinary dopamine as a potential index of the transport activity of multidrug and toxin extrusion in the kidney. Int J Mol Sci 17:1228CrossRefPubMedCentralGoogle Scholar
  180. Kalliokoski A, Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Brit J Pharmacol 158:693–705CrossRefGoogle Scholar
  181. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M (2008) Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol 48:311–321CrossRefPubMedGoogle Scholar
  182. Kamal MA, Keep RF, Smith DE (2008) Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity. Drug Metab Pharmacokinet 23:236–242CrossRefPubMedPubMedCentralGoogle Scholar
  183. Kamal MA, Jiang H, Hu Y, Keep RF, Smith DE (2009) Influence of genetic knockout of PEPT2 on the in vivo disposition of endogenous and exogenous carnosine in wild-type and PEPT2 null mice. Am J Physiol Regul Integr Comp Physiol 296:R986–R991CrossRefPubMedPubMedCentralGoogle Scholar
  184. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y et al (2012) Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug−drug interactions. J Med Chem 55:4740–4763CrossRefPubMedPubMedCentralGoogle Scholar
  185. Kato K, Shirasaka Y, Kuraoka E, Kikuchi A, Iguchi M, Suzuki H et al (2010) Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport. Mol Pharm 7:1747–1756CrossRefPubMedGoogle Scholar
  186. Kato K, Mori H, Kito YM, Ito S, Inoue K et al (2014) Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins. Pharm Res 31:136–147CrossRefPubMedGoogle Scholar
  187. Keppler D (2014) The Roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. Drug Metab Dispos 42:561–565CrossRefGoogle Scholar
  188. Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E et al (2002) Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 12:591–595CrossRefPubMedGoogle Scholar
  189. Kikuchi T, Okamura T, Wakizaka H, Okada M, Odaka K, Yui J et al (2014) OAT3-mediated extrusion of the 99mTc-ECD metabolite in the mouse brain. J Cereb Blood Flow Metab 34:585–588CrossRefPubMedPubMedCentralGoogle Scholar
  190. Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, El-Kattan A et al (2012) Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm 9:3535–3542CrossRefPubMedGoogle Scholar
  191. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K (2005) Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20:379–386CrossRefPubMedPubMedCentralGoogle Scholar
  192. Kindla J, Müller F, Mieth M, Fromm MF, König J (2011) Influence of non-steroidal anti- inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos 39:1047–1053CrossRefPubMedGoogle Scholar
  193. Kinoshita J, Iwata N, Kimotsuki T, Yasuda M (2014) Digoxin-induced reversible dysfunction of the cone photoreceptors in monkeys. Invest Ophthalmol Vis Sci 55:881–892CrossRefGoogle Scholar
  194. Kis O, Zastre JA, Ramaswamy M, Bendayan R (2010) pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug–drug interactions. J Pharmacol Exp Ther 334:1009–1022CrossRefPubMedGoogle Scholar
  195. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW (2008) Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 47:570–578CrossRefPubMedGoogle Scholar
  196. Klein K, Jüngst C, Mwinyi J, Stieger B, Krempler F, Patsch W et al (2010) The human organic anion transporter genes OAT5 and OAT7 are transactivated by hepatocyte nuclear factor-1α (HNF-1α). Mol Pharmacol 78:1079–1087CrossRefPubMedGoogle Scholar
  197. Klen J, Goričar K, Janež A, Dolžan V (2014) The role of genetic factors and kidney and liver function in glycemic control in type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment. Biomed Res Int 2014:934729CrossRefPubMedPubMedCentralGoogle Scholar
  198. Knütter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K et al (2008) Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther 327:432–441CrossRefPubMedGoogle Scholar
  199. Knütter I, Kottra G, Fischer W, Daniel H, Brandsch M (2009) High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos 37:143–149CrossRefPubMedGoogle Scholar
  200. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama YT (2005) Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol 57:573–578CrossRefGoogle Scholar
  201. Koepsell H (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Asp Med 34:413–435CrossRefGoogle Scholar
  202. Koepsell H, Lips K, Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227–1251CrossRefGoogle Scholar
  203. König J, Seithel A, Gradhand U, Fromm MF (2006) Pharmacogenomics of human OATP transporters. Naunyn Schmiedeberg’s Arch Pharmacol 372:432–443CrossRefGoogle Scholar
  204. König J, Zolk O, Singer K, Hoffmann C, Fromm MF (2011) Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Brit J Pharmacol 163:546–555CrossRefGoogle Scholar
  205. Koren-Michowitz M, Buzaglo Z, Ribakovsky E, Schwarz M, Pessach I, Shimoni A et al (2014) OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients. Eur J Haematol 92:283–288CrossRefPubMedGoogle Scholar
  206. Kotsampasakou E, Brenner S, Jäger W, Ecker GF (2015) Identification of novel inhibitors of organic anion transporting polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) using a consensus vote of six classification models. Mol Pharm 12:4395–4404CrossRefPubMedPubMedCentralGoogle Scholar
  207. Kozak R, Campbell BM, Strick CA, Horner W, Hoffmann WE, Kiss T et al (2014) Reduction of brain kynurenic acid improves cognitive function. J Neurosci 34:10592–10602CrossRefPubMedGoogle Scholar
  208. Kudo M, Katayoshi T, Kobayashi-Nakamura K, Akagawa M, Tsuji-Naito K (2016) H+/peptide transporter (PEPT2) is expressed in human epidermal keratinocytes and is involved in skin oligopeptide transport. Biochem Biophys Res Commun 475:335–341CrossRefPubMedGoogle Scholar
  209. Kullak-Ublick GA, . Ismair MG, Stieger B, Landmann L, Huber R, . Pizzagalli F et al (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525-533CrossRefPubMedGoogle Scholar
  210. Kunii E, Oguri T, Kasai D, Ozasa H, Uemura T, Takakuwa O et al (2015) Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer. Cancer Chemother Pharmacol 75:985–991CrossRefPubMedGoogle Scholar
  211. Kunze A, Huwyler J, Camenisch G, Poller B (2014) Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data. Drug Metab Dispos 42:1514–1521CrossRefPubMedGoogle Scholar
  212. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y et al (2011) Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 89:837–844CrossRefPubMedPubMedCentralGoogle Scholar
  213. Lacy SA, Hitchcock MJ, Lee WA, Tellier P, Cundy KC (1998) Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci 44:97–106CrossRefGoogle Scholar
  214. Lau YY, Huang Y, Frassetto L, Benet LZ (2007) Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194–204CrossRefPubMedPubMedCentralGoogle Scholar
  215. Lautem A, Heise M, Gräsel A, Hoppe-Lotichius M, Weiler N, Foltys D et al (2013) Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. Int J Oncol 42:1297–1304CrossRefPubMedGoogle Scholar
  216. Lazar A, Walitza S, Jetter A, Gerlach M, Warnke A, Herpertz-Dahlmann B et al (2008) Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive–compulsive disorder. Int J Neuropsychopharmacol 11:35–48CrossRefPubMedGoogle Scholar
  217. Lee A, Cooper MG, Craig JC, Knight JF, Keneally JP (1999) The effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on postoperative renal function: a meta-analysis. Anaesth Intensive Care 27:574–580CrossRefPubMedGoogle Scholar
  218. Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G et al (2005) Polymorphisms in human organic anion transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 280:9610–9617CrossRefGoogle Scholar
  219. Lee HH, Leake BF, Teft W, Tirona RG, . Kim RB, Ho RH (2015) Contribution of hepatic organic anion transporting polypeptides (OATPs) to docetaxel uptake and clearance. Mol Cancer Ther 14: 994-1003.CrossRefPubMedPubMedCentralGoogle Scholar
  220. Lepist EI, Zhang X, Hao J, Huang J, osaka A, irkus G et al (2014) Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int 86:350–357CrossRefPubMedPubMedCentralGoogle Scholar
  221. Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, Stieger B (2009) Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol 296:C570–C582CrossRefPubMedGoogle Scholar
  222. Li L, Lee TK, Meier PJ, Ballatori N (1998) Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp 1, the hepatic sinusoidal organic solute transporter. J Biol Chem 273:16184–16191CrossRefPubMedGoogle Scholar
  223. Li Q, Liu F, Zheng TS, Tang JL, Lu HJ, Jia WP (2010) SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin. Acta Pharmacol Sin 31:184–190CrossRefPubMedPubMedCentralGoogle Scholar
  224. Li S, Chen Y, Zhang S, More SS, Huang X, Giacomini KM (2011) Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine (pyridine) chloroplatinum (II) and oxaliplatin in mice. Pharm Res 28:610–625CrossRefPubMedGoogle Scholar
  225. Li LM, Chen L, Deng GH, Tan WT, Dan YJ, Wang RQ (2012) SLCO1B1∗15 haplotype is associated with rifampin-induced liver injury. Mol Med Rep 6:75–82PubMedGoogle Scholar
  226. Li L, Agarwal S, Elmquist WF (2013a) Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate. Drug Metab Dispos 41:659–667CrossRefPubMedPubMedCentralGoogle Scholar
  227. Li Q, Guo D, Dong Z, Zhang W, Zhang L, Huang SM et al (2013b) Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicol Appl Pharmacol 273:100–109CrossRefGoogle Scholar
  228. Li L, Tu M, Yang X, Sun S, Wu X, Zhou H et al (2014) The contribution of human OCT1, OCT3, and CYP3A4 to nitidine chloride-induced hepatocellular toxicity. Drug Metab Dispos 42:1227–1234CrossRefGoogle Scholar
  229. Lickteig AJ, Cheng X, Augustine LM, Klaassen CD, Cherrington NJ (2008) Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. Life Sci 83:59–64CrossRefPubMedPubMedCentralGoogle Scholar
  230. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ (2003) Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther 73:192–198CrossRefPubMedPubMedCentralGoogle Scholar
  231. Lilja JJ, Juntti-Patinen L, Neuvonen PJ (2004) Orange juice substantially reduces the bioavailability of the β-adrenergic–blocking agent celiprolol. Clin Pharmacolo Ther 75:184–190CrossRefGoogle Scholar
  232. Lilja JJ, Raaska K, Neuvonen PJ (2005) Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol 61:337–340CrossRefPubMedPubMedCentralGoogle Scholar
  233. Lim CK, Fernández-Gomez FJ, Braidy N, Estrada C, Costa C, Costa S et al (2017) Involvement of the kynurenine pathway in the pathogenesis of Parkinson’s disease. Prog Neurobiol 155:76–95CrossRefPubMedPubMedCentralGoogle Scholar
  234. Lin CJ, Tai Y, Huang MT, Tsai YF, Hsu HJ, Tzen KY et al (2010) Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents. J Neurochem 114:717–727CrossRefPubMedPubMedCentralGoogle Scholar
  235. Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G et al (2012) Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 38:426–432CrossRefPubMedPubMedCentralGoogle Scholar
  236. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F et al (2008) SLCO1B1 variants and statin-induced myopathy -a genomewide study. N Engl J Med 359:789–799CrossRefPubMedPubMedCentralGoogle Scholar
  237. Lips KS, Volk C, Schmitt BM, Pfeil U, Arndt P, Miska D et al (2005) Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol 33:79–88CrossRefPubMedPubMedCentralGoogle Scholar
  238. Liu R, Tang AM, Tan YL, Limenta LM, Lee EJ (2011) Effects of sodium bicarbonate and ammonium chloride pre-treatments on PEPT2 (SLC15A2) mediated renal clearance of cephalexin in healthy subjects. Drug Metab Pharmacokinet 26:87–93CrossRefGoogle Scholar
  239. Liu HC, Jamshidi N, Chen Y, Eraly SA, Cho SY, Bhatnagar V et al (2016) An organic anion transporter 1 (OAT1)-centered metabolic network. J Biol Chem 291:19474–19486CrossRefPubMedPubMedCentralGoogle Scholar
  240. Liu JE, Liu XY, Chen S, Zhang Y, Cai LY, Yang M et al (2017) SLCO1B1 521T>C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol 73:1409–1416CrossRefPubMedPubMedCentralGoogle Scholar
  241. Lopez JL, Tayek JA (2016) Voriconazole-induced hepatitis via simvastatin- and lansoprazole-mediated drug interactions: A case report and review of the literature. Drug Metab Dispos 44:124–126CrossRefPubMedGoogle Scholar
  242. Losordo DW, Isner JM, Diaz-Sandoval LJ (2003) Endothelial recovery: the next target in restenosis prevention. Circulation 107:2635–2637CrossRefPubMedGoogle Scholar
  243. Lozano E, Herraez E, Briz O, Robledo VS, Hernandez-Iglesias J, Gonzalez-Hernandez A et al (2013) Role of the plasma membrane transporter of organic cations oct 1 and its genetic variants in modern liver pharmacology. Biomed Res Int 2013:692071CrossRefPubMedPubMedCentralGoogle Scholar
  244. Lu X, Chan T, Xu C, Zhu L, Zhou QT, Roberts KD et al (2016) Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins. J Antimicrob Chemother 71:403–412CrossRefGoogle Scholar
  245. Maeda K (2015) Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs. Biol Pharm Bull 38:155–168CrossRefGoogle Scholar
  246. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K et al (2006) Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 79:427–439CrossRefGoogle Scholar
  247. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y et al (2011) Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90:575–581CrossRefPubMedPubMedCentralGoogle Scholar
  248. Maeda K, Tian Y, Fujita T, Ikeda Y, Kumagai Y, Kondo T et al (2014) Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans. Eur J Pharm Sci 59:94–103CrossRefGoogle Scholar
  249. Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N (2007) Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am J Physiol Gastrointest Liver Physiol 293:G271–G278CrossRefPubMedGoogle Scholar
  250. Marada VV, Flörl S, Kühne A, Müller J, Burckhardt G, Hagos Y (2015) Interaction of human organic anion transporter 2 (OAT2) and sodium taurocholate cotransporting polypeptide (NTCP) with antineoplastic drugs. Pharmacol Res 91:78–87CrossRefGoogle Scholar
  251. Martina V, Benso A, Gigliardi VR, Masha A, Origlia C, Granata R et al (2006) Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects. Clin Endocrinol 64:260–264CrossRefGoogle Scholar
  252. Martinez-Becerra P, Briz O, Romero MR, Macias RI, Perez MJ, Sancho-Mateo C et al (2011) Further characterization of the electrogenicity and pH sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3. Mol Pharmacol 79:596–607CrossRefPubMedPubMedCentralGoogle Scholar
  253. Masereeuw R, Mutsaers HA, Toyohara T, Abe T, Jhawar S, Sweet DH et al (2014) The kidney and uremic toxin removal: glomerulus or tubule? Semin Nephrol 34:191–208CrossRefPubMedPubMedCentralGoogle Scholar
  254. Matsumoto J, Ariyoshi N, Sakakibara M, Nakanishi T, Okubo Y, Shiina N et al (2015) Organic anion transporting polypeptide 2B1 expression correlates with uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive breast cancer cells. Drug Metabo Pharmacokinet 30:133–141CrossRefGoogle Scholar
  255. Matsumura K, Arima H, Tominaga M, Ohtsubo T, Sasaguri T, Fujii K et al (2015) Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study. Clin Exp Hypertens 37:192–196CrossRefPubMedPubMedCentralGoogle Scholar
  256. Mayerl S, Müller J, Bauer R, Richert S, Kassmann CM, Darras VM et al (2014) Transporters MCT8 and OATP1C1maintain murine brain thyroid hormone homeostasis. J Clin Invest 124:1987–1999CrossRefPubMedPubMedCentralGoogle Scholar
  257. McAdams DeMarco MA, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A et al (2012) Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the atherosclerosis risk in Communities cohort study. Arthritis Rheum 64:121–129CrossRefPubMedPubMedCentralGoogle Scholar
  258. Meier-Abt F, Mokrab Y, Mizuguchi K (2005) Organic anion transporting polypeptides of the oatp/slco superfamily: identification of new members in nonmammalian species, comparative modeling and a potential transport mode. J Membrane Biol 208:213–227CrossRefGoogle Scholar
  259. Merlin D, Si-Tahar M, Sitaraman SV, Eastburn K, Williams I, Liu X et al (2001) Colonic epithelial hPEPT1 expression occurs in inflammatory bowel disease: transport of bacterial peptides influences expression of MHC class 1molecules. Gastroenterology 120:1666–1679CrossRefPubMedPubMedCentralGoogle Scholar
  260. Meyer Zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB (2008) Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res 68:9338–9347CrossRefPubMedPubMedCentralGoogle Scholar
  261. Meyer zu Schwabedissen HE, Ware JA, Finkelstein D, Chaudhry AS, Lemay S, Leon-Ponte M et al (2011) Hepatic OATP transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis. Hepatology 54:644–654CrossRefPubMedPubMedCentralGoogle Scholar
  262. Meyer zu Schwabedissen HE, Boettcher K, Steiner T, Schwarz UI, Keiser M, Kroemer HK et al (2014) OATP1B3 is expressed in pancreatic β-islet cells and enhances the insulinotropic effect of the sulfonylurea derivative glibenclamide. Diabetes 63:775–784CrossRefPubMedPubMedCentralGoogle Scholar
  263. Miki Y, Suzuki T, Kitada K, Yabuki N, Shibuya R, Moriya T et al (2006) Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res 66:535–542CrossRefPubMedPubMedCentralGoogle Scholar
  264. Minematsu T, Giacomini KM (2011) Interactions of tyrosine kinase inhibitors with organic cation transporters, OCTs, and multidrug and toxic compound extrusion proteins, MATEs. Mol Cancer Ther 10:531–539CrossRefPubMedPubMedCentralGoogle Scholar
  265. Misaka S, Yatabe J, Muller F, Takano K, Kawabe K, Glaeser H et al (2014) Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. Clin Pharmacol Ther 95:432–438CrossRefPubMedPubMedCentralGoogle Scholar
  266. Mitsuoka K, Miyoshi S, Kato Y, Murakami Y, Utsumi R, Kubo Y et al (2008) Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporter. J Nucl Med 49:615–622CrossRefPubMedPubMedCentralGoogle Scholar
  267. Miyajima M, Kusuhara H, Fujishima M, Adachi Y, i Sugiyama Y (2011) Organic anion transporter 3 mediates the efflux transport of an amphipathic organic anion, dehydroepiandrosterone sulfate, across the blood-brain barrier in mice. Drug Metab Dispos 39:814–819CrossRefPubMedPubMedCentralGoogle Scholar
  268. Moore KH, Yuen GJ, Raasch RH, Eron JJ, Martin D, Mydlow PK et al (1996) Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 59:550–558CrossRefPubMedPubMedCentralGoogle Scholar
  269. Moreno A, Fortún J, Graus J, Rodriguez-Gandía MA, Quereda C, Pérez-Elías MJ et al (2011) Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia. Liver Transpl 17:331–333CrossRefPubMedPubMedCentralGoogle Scholar
  270. Motohashi H, Inui K (2013) Organic Cation Transporter OCT (SLC22) and MATEs (SLC47) in the human kidney. AAPS J 15:581–588CrossRefPubMedPubMedCentralGoogle Scholar
  271. Mück W, Ochmann K, Rohde G, Unger S, Kuhlmann J (1998) Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 53:469–473CrossRefPubMedPubMedCentralGoogle Scholar
  272. Mück W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S et al (1999) Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 65:251–261CrossRefPubMedPubMedCentralGoogle Scholar
  273. Mulato AS, Ho ES, Cihlar T (2000) Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther 295:10–15PubMedPubMedCentralGoogle Scholar
  274. Mulgaonkar A, Venitz J, Gründemann D, Sweet DH (2013) Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials. Antimicrob Agents Chemother 57:2705–2711CrossRefPubMedPubMedCentralGoogle Scholar
  275. Müller F, König J, Hoier E, Mandery K, Fromm MF (2013) Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochem Pharmacol 86:808–815CrossRefPubMedPubMedCentralGoogle Scholar
  276. Müller F, Pontones CA, Renner BR, Mieth M, Hoier E et al (2015) N1-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin–trimethoprim interaction. Eur J Clin Pharmacol 71:85–94CrossRefPubMedPubMedCentralGoogle Scholar
  277. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T (2004) Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75:415–421CrossRefPubMedPubMedCentralGoogle Scholar
  278. Nagle MA, Wu W, Eraly SA, Nigam SK (2013) Organic anion transport pathways in antiviral handling in choroid plexus in Oat 1 (Slc 22a6) and Oat 3 (Slc 22a8) deficient tissue. Neurosci Lett 534:133–138CrossRefPubMedPubMedCentralGoogle Scholar
  279. Nakakariya M, Shimada T, Irokawa M, Maeda T, Tamai I (2008) Identification and species similarity of OATP transporters responsible for hepatic uptake of β-lactam antibiotics. Drug Metab Pharmacokinet 23:347–355CrossRefPubMedPubMedCentralGoogle Scholar
  280. Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui KI (2010) Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharamcol 80:762–1767CrossRefGoogle Scholar
  281. Nakanishi T, Tamai I (2017) Roles of Organic Anion Transporting Polypeptide 2A1 (OATP2A1/SLCO2A1) in Regulating the Pathophysiological Actions of Prostaglandins. AAPS J 20:13CrossRefPubMedPubMedCentralGoogle Scholar
  282. Nässl AM, Rubio-Aliaga I, Fenselau H, Marth MK, Kottra G, Daniel H (2011) Amino acid absorption and homeostasis in mice lacking the intestinal peptide transporter PEPT1. Am J Physiol Gastrointest Liver Physiol 301:G128–G137CrossRefPubMedPubMedCentralGoogle Scholar
  283. Nguyen HT, Dalmasso G, Powell KR, Yan Y, Bhatt S, Kalman D et al (2009) Pathogenic bacteria induce colonic Pep T1 expression: an implication in host defense response. Gastroenterology 137:1435–1447CrossRefPubMedPubMedCentralGoogle Scholar
  284. Niemi M, Pasanen MK, Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157–181CrossRefPubMedPubMedCentralGoogle Scholar
  285. Nies AT, Schwab M, Keppler D (2008) Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol 4:545–568CrossRefGoogle Scholar
  286. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R et al (2009) Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50:1227–1240CrossRefPubMedPubMedCentralGoogle Scholar
  287. Nies AT, Damme K, Kruck S, Schaeffeler E, Schwab M (2016) Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine. Arch Toxicol 90:1555–1584CrossRefPubMedPubMedCentralGoogle Scholar
  288. Nieskens TT, Peters JG, Schreurs MJ, Smits N, Woestenenk R, Jansen K et al (2016) A human renal proximal tubule cell line with stable organic anion transporter 1 and 3 expression predictive for antiviral-induced toxicity. AAPS J 18:465–475CrossRefPubMedPubMedCentralGoogle Scholar
  289. Niessen J, Jedlitschky G, Grube M, Bien S, Schwertz H, Ohtsuki S et al (2009) Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metabo Dispo 37:1129–1137CrossRefGoogle Scholar
  290. Nieuweboer AJM, Hu S, Hagenbuch B, Moghaddam-Helmantel JG, Gibson AA, de Bruijn P et al (2014) Influence of drug formulation on OATP1B-mediated transport of paclitaxel. Cancer Res 74:3137–3145CrossRefPubMedPubMedCentralGoogle Scholar
  291. Nigam SK, Wu W, Bush KT, Hoenig MP, Blantz RC, Bhatnagar V (2015) Handling of drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters. Clin J Am Soc Nephrol 10:2039–2049Google Scholar
  292. Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindströ MLH et al (2005) Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 80:315–322CrossRefPubMedPubMedCentralGoogle Scholar
  293. Nishino S, Itoh A, Matsuoka H, Maeda K, Kamoshida S (2013) Immunohistochemical analysis of organic anion transporter 2 and reduced folate carrier 1 in colorectal cancer: significance as a predictor of response to oral uracil/ftorafur plus leucovorin chemotherapy. Mol Clin Oncol 1:661–667PubMedPubMedCentralGoogle Scholar
  294. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T et al (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554–565CrossRefPubMedPubMedCentralGoogle Scholar
  295. Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, Renner EL, Clavien PA (2007) Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology 133:608–618CrossRefPubMedGoogle Scholar
  296. Noé J, Portmann R, Brun ME, Funk C (2007) Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35:1308–1314CrossRefPubMedGoogle Scholar
  297. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I (2004) Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 308:438–445CrossRefPubMedPubMedCentralGoogle Scholar
  298. Obach RS, Lombardo F, Waters NJ (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36:1385–1405CrossRefPubMedGoogle Scholar
  299. Obaidat A, Roth M, Hagenbuch B (2012) The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 52:135–151CrossRefPubMedGoogle Scholar
  300. Ocheltree SM, Shen H, Hu Y, Keep RF, Smith DE (2005) Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther 315:240–247CrossRefPubMedGoogle Scholar
  301. Oguri T, Kunii E, Fukuda S, Sone K, Uemura T, Takakuwa O et al (2016) Organic cation transporter 6 directly confers resistance to anticancer platinum drugs. Biomed Rep 5:639–643CrossRefPubMedPubMedCentralGoogle Scholar
  302. Ohishi Y, Nakamuta M, Ishikawa N, Saitoh O, Nakamura H, Aiba Y et al (2014) Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol 49:332–342CrossRefPubMedGoogle Scholar
  303. Ohta KY, Imamura Y, Okudaira N, Atsumi R, Inoue K, Yuasa H (2009) Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther 328:628–634CrossRefPubMedGoogle Scholar
  304. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M (2002) Role of blood–brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem 83:57–66CrossRefPubMedGoogle Scholar
  305. Ohya H, Shibayama Y, Ogura J, Narumi K, Kobayashi M, Iseki K (2015) Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol Pharm Bull 38:582–586CrossRefPubMedGoogle Scholar
  306. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A 102:17923–17928CrossRefPubMedPubMedCentralGoogle Scholar
  307. Pak YA, Long AJ, Annes WF, Witcher JW, Knadler MP, Ayan-Oshodi MA et al (2017) In vitro and clinical evaluations of the drug-drug interaction potential of a metabotropic glutamate 2/3 receptor agonist prodrug with intestinal peptide transporter 1. Drug Metab Dispos 45:137–144CrossRefPubMedPubMedCentralGoogle Scholar
  308. Pasanen MK, Backman JT, Neuvonen PJ, Niemi M (2006a) Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol 62:409–415CrossRefPubMedGoogle Scholar
  309. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M (2006b) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16:873–879CrossRefPubMedGoogle Scholar
  310. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726–733CrossRefGoogle Scholar
  311. Pasanen MK, Neuvonen PJ, Niemi M (2008) Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9:19–33CrossRefPubMedGoogle Scholar
  312. Pathan E, Gaitonde S, Rajadhyaksha S, Sule A, Mittal G, Joshi VR (2003) A longitudinal study of serum creatinine levels in patients of rheumatoid arthritis on long term NSAID therapy. J Assoc Physicians India 51:1045–1049PubMedGoogle Scholar
  313. Pfennig T, Herrmann B, Bauer T, Schömig E, Gründemann D (2013) Benzoic acid and specific 2-oxo acids activate hepatic efflux of glutamate at OAT2. Biochim Biophys Acta 1828:491–498CrossRefPubMedGoogle Scholar
  314. Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung JK, Gerretsen P et al (2017) Kynurenic acid in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 43(Suppl 1):S211CrossRefPubMedCentralGoogle Scholar
  315. Posada MM, Smith DE (2013a) Relevance of Pep T1 in the intestinal permeability and oral absorption of cefadroxil. Pharm Res 30:1017–1025CrossRefPubMedGoogle Scholar
  316. Posada MM, Smith DE (2013b) In vivo absorption and disposition of cefadroxil after escalating oral doses in wild-type and Pep T1 knockout mice. Pharm Res 30:2931–2939CrossRefPubMedGoogle Scholar
  317. Prado Y, Saavedra N, Zambrano T, Lagos J, Rosales A, Salazar LA (2015) SLCO1B1 c.388A>G polymorphism is associated with HDL-C levels in response to atorvastatin in Chilean individuals. Int J Mol Sci 16:20609–20619Google Scholar
  318. Qian CY, Zheng Y, Wang Y, Chen J, Liu JY, Zhou HH et al (2016) Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. Chin J Cancer 35:85CrossRefPubMedPubMedCentralGoogle Scholar
  319. Rawłuszko-Wieczorek AA, Horst N, Horbacka K, Bandura AS, Świderska M, Krokowicz P et al (2015) Effect of DNA methylation profile on OATP3A1 and OATP4A1 transcript levels in colorectal cancer. Biomed Pharmacother 74:233–242CrossRefPubMedGoogle Scholar
  320. Regazzi MB, Campana IC, Raddato V, Lesi C, Perani G, Gavazzi A et al (1993) Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 25:2732–2734PubMedGoogle Scholar
  321. Rizwan AN, Burckhardt G (2007) Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 24:450–470CrossRefGoogle Scholar
  322. Rodrigues AC, Perin PMS, Purim RG, Silbiger VN, Genvigir FDV, Willrich MAV et al (2011) Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci 12:5815–5827CrossRefPubMedPubMedCentralGoogle Scholar
  323. Römermann K, Fedrowitz M, Hampel P, Kaczmarek E, Töllner K, Erker T et al (2017) Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain. Neuropharmacology 117:182–194CrossRefPubMedGoogle Scholar
  324. Roth M, Timmermann BN, Hagenbuch B (2011) Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metab Dispos 39:920–926CrossRefPubMedPubMedCentralGoogle Scholar
  325. Roth M, Obaidat A, Hagenbuch B (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Brit J Pharmacol 165:1260–1287CrossRefGoogle Scholar
  326. Russel FG, Masereeuw R, van Aubel RA (2002) Molecular aspects of renal anionic drug transport. Annu Rev Physiol 64:563–594CrossRefPubMedGoogle Scholar
  327. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I et al (2006) Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos 34:1423–1431CrossRefPubMedGoogle Scholar
  328. Salazar DE, Schentag JJ, Corcoran GB (1992) Obesity as a risk factor in drug-induced organ injury. V. Toxicokinetics of gentamicin in the obese overfed rat. Drug Metab Dispos 20:402–406PubMedGoogle Scholar
  329. Salphati L (2009) Transport-metabolism interplay. Mol Pharm 6:1629–1630CrossRefPubMedGoogle Scholar
  330. Satlin LM, Amin V, Wolkoff AW (1997) Organic anion transporting polypeptide mediates organic anion/HCO3- exchange. J Biol Chem 272:26340–26345CrossRefPubMedGoogle Scholar
  331. Sato M, Iwanaga T, Mamada H, Ogihara T, Yabuuchi H, Maeda T et al (2008) Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res 25:639–646CrossRefPubMedGoogle Scholar
  332. Sato M, Mamada H, Anzai N, Shirasaka Y, Nakanishi T, Tamai I (2010) Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLC22A7) in human. Biol Pharm Bull 33:498–503CrossRefPubMedGoogle Scholar
  333. Sato T, Mishima E, Mano N, Abe T, Yamaguchi H (2017) Potential drug interactions mediated by renal organic anion transporter OATP4C1. J Pharmacol Exp Ther 362:271–277CrossRefPubMedGoogle Scholar
  334. Sauzay C, White-Koning M, Hennebelle I, Deluche T, Delmas C, Imbs DC et al (2016) Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin. Pharmacol Res 110:89–95CrossRefPubMedGoogle Scholar
  335. Schwarcz R, Pellicciari R (2002) Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303:1–10CrossRefPubMedGoogle Scholar
  336. Seitz T, Stalmann R, Dalila N, Chen J, Pojar S, Dos Santos Pereira JN et al (2015) Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1. Genome Med 7:56CrossRefPubMedPubMedCentralGoogle Scholar
  337. Seki S, Kobayashi M, Itagaki S, Hirano T, Iseki K (2009) Contribution of organic anion transporting polypeptide OATP2B1 to amiodarone accumulation in lung epithelial cells. Biochim Biophys Acta 1788:911–917CrossRefPubMedGoogle Scholar
  338. Shen H, Ocheltree SM, Hu Y, Keep RF, Smith DE (2007) Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption and brain penetration in mice. Drug Metab Dispos 35:1209–1296CrossRefPubMedGoogle Scholar
  339. Shen H, Liu T, Morse BL, Zhao Y, Zhang Y, Qiu X et al (2015) Characterization of organic anion transporter 2 (SLC22A7): a highly efficient transporter for creatinine and species-dependent renal tubular expression. Drug Metab Dispos 43:984–993CrossRefPubMedGoogle Scholar
  340. Shen H, Dai J, Liu T, Cheng Y, Chen W, Freeden C et al (2016) Coproporphyrins I and III as Functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species. J Pharmacol Exp Ther 357:382–393CrossRefPubMedGoogle Scholar
  341. Shimakata T, Kamoshida S, Kawamura J, Ogane N, Kameda Y, Yanagita E et al (2016) Immunohistochemical expression profiles of solute carrier transporters in alpha-fetoprotein-producing gastric cancer. Histopathology 69:812–821CrossRefPubMedGoogle Scholar
  342. Shirasaka Y, Shichiri M, Mori T, Nakanishi T, Tamai I (2013) Major active components in grapefruit, orange, and apple juices responsible for OATP2B1-mediated drug interactions. J Pharm Sci 102:3418–3426CrossRefPubMedGoogle Scholar
  343. Shitara Y (2011) Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. Drug Metab Pharmacokinet 26:220–227CrossRefPubMedPubMedCentralGoogle Scholar
  344. Shitara Y, Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71–105CrossRefPubMedGoogle Scholar
  345. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug–drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610–616CrossRefPubMedPubMedCentralGoogle Scholar
  346. Shitara Y, Hirano M, Sato H, Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228–236CrossRefPubMedGoogle Scholar
  347. Shitara Y, Nagamatsu Y, Wada S, Sugiyama Y, Horie T (2009) Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin a in rats. Drug Metab Dispos 37:1172–1178CrossRefPubMedGoogle Scholar
  348. Shitara Y, Takeuchi K, Nagamatsu Y, Wada S, Sugiyama Y, Horie T (2012) Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake. Drug Metab Pharmacokinet 27:368–378CrossRefPubMedPubMedCentralGoogle Scholar
  349. Shitara Y, Maeda K, Ikejiri YK, Horie T, Sugiyama Y (2013a) Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 34:45–78CrossRefGoogle Scholar
  350. Shitara Y, Takeuchi K, Horie T (2013b) Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake. J Pharm Sci 102:3427–3435CrossRefPubMedPubMedCentralGoogle Scholar
  351. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA et al (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422–1431CrossRefPubMedPubMedCentralGoogle Scholar
  352. Shu N, Hu M, Ling Z, Liu P, Wang F, Xu P et al (2016a) The enhanced atorvastatin hepatotoxicity in diabetic rats was partly attributed to the upregulated hepatic Cyp 3a and SLCO1B1. Sci Rep 6:33072CrossRefPubMedPubMedCentralGoogle Scholar
  353. Shu N, Hu M, Liu C, Zhang M, Ling Z, Zhang J et al (2016b) Decreased exposure of atorvastatin in diabetic rats partly due to induction of hepatic Cyp 3a and Oatp 2. Xenobiotica 46:875–881CrossRefPubMedPubMedCentralGoogle Scholar
  354. Sleijfer DT, Offerman JJ, Mulder NH, Verweij M, van der Hem GK, Schraffordt Koops HS et al (1987) The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 60:2823–2282CrossRefPubMedPubMedCentralGoogle Scholar
  355. Smith DE, Hu Hu Y, Shen H, Nagaraja TN, Fenstermacher JD, Keep RF (2011) Distribution of glycylsarcosine and cefadroxil among cerebrospinal fluid, choroid plexus, and brain parenchyma after intracerebroventricular injection is markedly different between wild-type and Pept 2 null mice. J Cereb Blood Flow Metab 31:250–261CrossRefPubMedPubMedCentralGoogle Scholar
  356. Smith DE, Clémençon B, Hediger MA (2013) Proton-coupled oligopeptide transporter family SLC15: Physiological, pharmacological and pathological implications. Mol Asp Med 34:323–336CrossRefGoogle Scholar
  357. Sobin C, Flores-Montoya MG, Gutierrez M, Parisi N, Schaub T (2015) δ-Aminolevulinic acid dehydratase single nucleotide polymorphism 2 (ALAD2) and peptide transporter 2∗2 haplotype (hPEPT2∗2) differently influence neurobehavior in low-level lead exposed children. Neurotoxicol Teratol 247:137–145CrossRefGoogle Scholar
  358. Song IS, Shin HJ, Shin JG (2008) Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes. Xenobiotica 38:1252–1262CrossRefGoogle Scholar
  359. Sprowl JA, van Doorn L, Hu S, van Gerven L, de Bruijn P, Li L et al (2013) Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther 94:585–592CrossRefPubMedPubMedCentralGoogle Scholar
  360. Sprowl S, Lancaster CS, Pabla N, Hermann E, Kosloske AM, Gibson AA et al (2014) Cisplatin- induced renal injury is independently mediated by OCT2 and p 53. Clin Cancer Res 20:4026–4035CrossRefPubMedPubMedCentralGoogle Scholar
  361. Stamer UM, Musshoff F, Stüber F, Brockmöller J, Steffens M, Tzvetkov MV (2016) Loss-of- function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption. Pain 157:2467–2475CrossRefPubMedGoogle Scholar
  362. Staud F, Cerveny L, Ahmadimoghaddam D, Ceckova M (2013) Multidrug and toxin extrusion proteins (MATE/SLC47); role in pharmacokinetics. Int J Biochem Cell Biol 45:2007–2011CrossRefGoogle Scholar
  363. Stefanko E, Rybka J, Jaźwiec B, Haus O, Stąpor S, Kuliczkowski K et al (2017) Significance of OCT1 expression in acute myeloid leukemia. Pathol Oncol Res 23:665–671CrossRefGoogle Scholar
  364. Stelzl T, Baranov T, Geillinger KE, Kottra G, Daniel H (2016) Effect of N-glycosylation on the transport activity of the peptide transporter PEPT1. Am J Physiol Gastrointest Liver Physiol 310:G128–G411CrossRefPubMedPubMedCentralGoogle Scholar
  365. Stelzl T, Geillinger-Kästle KE, Stolz J, Daniel H (2017) Glycans in the intestinal peptide transporter PEPT1 contribute to function and protect from proteolysis. Am J Physiol Gastrointest Liver Physiol 312:G580–G591CrossRefGoogle Scholar
  366. Sticova E, Lodererova A, van de Steeg E, Frankova S, Kollar M, Lanska V et al (2015) Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis. Int J Clin Exp Pathol 8:5252–5262PubMedPubMedCentralGoogle Scholar
  367. Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A et al (2013) The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 93:186–194CrossRefGoogle Scholar
  368. Suga T, Yamaguchi H, Sato T, Maekawa M, Goto J, Mano N (2017) Preference of conjugated bile acids over unconjugated bile acids as substrates for OATP1B1and OATP1B3. PLoS One 12:e0169719CrossRefPubMedPubMedCentralGoogle Scholar
  369. Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME (2000) Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci 89:781–789CrossRefGoogle Scholar
  370. Sun D, Wang Y, Tan F, Fang D, Hu Y, Smith DE et al (2013) Functional and molecular expression of the proton-coupled oligopeptide transporters in spleen and macrophages from mouse and human. Mol Pharm 10:1409–1416CrossRefPubMedPubMedCentralGoogle Scholar
  371. Sundelin EI, Gormsen LC, Jensen JB, Vendelbo MH, Jakobsen S, Munk OL et al (2017) Genetic polymorphisms in organic cation transporter 1 attenuates hepatic metformin exposure in humans. Clin Pharmacol Ther 102:841–848CrossRefGoogle Scholar
  372. Svoboda M, Wlcek K, Taferner B, Hering S, Stieger B, Tong D et al (2011) Expression of oranion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother 65:417–426CrossRefPubMedPubMedCentralGoogle Scholar
  373. Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J et al (2004) Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 19:375–380CrossRefPubMedPubMedCentralGoogle Scholar
  374. Tachikawa M, Ozeki G, Higuchi T, Akanuma S, Tsuji K, Hosoya K (2012a) Role of the blood-cerebrospinal fluid barrier transporter as a cerebral clearance system for prostaglandin E2 produced in the brain. J Neurochem 123:750–760CrossRefGoogle Scholar
  375. Tachikawa M, Tsuji K, Yokoyama R, Higuchi T, Ozeki G, Yashiki A et al (2012b) A clearance system for prostaglandin D2, a sleep-promoting factor, in cerebrospinal fluid: role of the blood-cerebrospinal barrier transporters. J Pharmaacol Exp Ther 343:608–616CrossRefGoogle Scholar
  376. Tachikawa M, Hosoya K, Terasaki T (2014) Pharmacological significance of prostaglandin E2 and D2 transport at the brain barriers. Adv Pharmacol 71:337–360CrossRefGoogle Scholar
  377. Taguchi T, Masuo Y, Kogi T, Nakamichi N, Kato Y (2016) Characterization of long-lasting Oatp inhibition by typical inhibitor cyclosporine a and in vitro-in vivo discrepancy in its drug interaction potential in rats. J Pharm Sci 105:2231–2239CrossRefPubMedPubMedCentralGoogle Scholar
  378. Tai W, Chen Z, Cheng K (2013) Expression profile and functional activity of peptide transporters in prostate cancer cells. Mol Pharm 10:477–487CrossRefPubMedPubMedCentralGoogle Scholar
  379. Takeda M, Narikawa S, Hosoyamada M, Cha SH, Sekine T, Endou H (2001) Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur J Pharmacol 419:113–120CrossRefPubMedPubMedCentralGoogle Scholar
  380. Takeda M, Babu E, Narikawa S, Endou H (2002) Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol 438:137–142CrossRefPubMedPubMedCentralGoogle Scholar
  381. Tamai I (2012) Oral drug delivery utilizing intestinal OATP transporters. Adv Drug Deliv Rev 64:508–514CrossRefGoogle Scholar
  382. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M et al (2000) Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273:251–260CrossRefGoogle Scholar
  383. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A (2001) Characterization of human organic anion polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 18:1262–1269CrossRefPubMedPubMedCentralGoogle Scholar
  384. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K (2007) Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 74:359–371CrossRefPubMedPubMedCentralGoogle Scholar
  385. Tanihara Y, Masuda S, Katsura T, Inui KI (2009) Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem Pharmacol 78:1263–1271CrossRefPubMedPubMedCentralGoogle Scholar
  386. Tapaninen T, Neuvonen PJ, Niem M (2011) Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol 71:718–726CrossRefPubMedPubMedCentralGoogle Scholar
  387. Tashiro A, Tatsumi S, Takeda R, Naka A, Matsuoka H, Hashimoto Y et al (2014) High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy. Am J Cancer Res 4:528–536PubMedPubMedCentralGoogle Scholar
  388. Taylor-Wells J, Meredith D (2014) The signature sequence region of the human drug transporter organic anion transporting polypeptide 1B1 is important for protein surface expression. J Drug Deliv 2014:129849CrossRefPubMedPubMedCentralGoogle Scholar
  389. Tchernitchko D, Tavernier Q, Lamoril J, Schmitt C, Talbi N, Lyoumi S et al (2017) A variant of peptide transporter 2 predicts the severity of porphyria-associated kidney disease. J Am Soc Nephrol 28:1924–1932CrossRefPubMedPubMedCentralGoogle Scholar
  390. Te Brake LH, van den Heuvel JJ, Buaben AO, van Crevel R, Bilos A, Russel FG et al (2016) Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol. Antimicrob Agents Chemother 60:7105–7114Google Scholar
  391. Teft WA, Welch S, Lenehan J, Parfitt J, Choi YH, Winquist E et al (2015) OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. Brit J Cancer 112:857–865CrossRefPubMedPubMedCentralGoogle Scholar
  392. Terada T, Inui K (2008) Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). Biochem Pharmacol 75:1689–1696CrossRefPubMedPubMedCentralGoogle Scholar
  393. Thakkar N, Kim K, Jang ER, Han S, Kim D, Merchant N, Lockhart AC, Lee W (2013) A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm 10:406–416CrossRefPubMedPubMedCentralGoogle Scholar
  394. Thwaites DT, Anderson CMH (2007) H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physio 92:603–619CrossRefGoogle Scholar
  395. Tirona RG, Leake BF, Merino G, Kim RB (2001) Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669–35675CrossRefPubMedPubMedCentralGoogle Scholar
  396. Tkáč L, Klimčáková L, Javorský M, Fabianová M, Schroner Z, Hermanová H et al (2013) Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes Metab 15:189–191CrossRefPubMedPubMedCentralGoogle Scholar
  397. Töllner K, Brandt C, Römermann K, Löscher W (2015) The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide. Eur J Pharmacol 746:167–173CrossRefPubMedPubMedCentralGoogle Scholar
  398. Torres AM, Dnyanmote AV, Bush KT, Wu W, Nigam SK (2011) Deletion of multispecific organic anion transporter Oat 1/Slc 22a6 protects against mercury-induced kidney injury. J Biol Chem 286:26391–26395CrossRefPubMedPubMedCentralGoogle Scholar
  399. Toyama K, Yonezawa A, Tsuda M, Masuda S, Yano I, Terada T et al (2010) Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenet Genomics 20:135–138CrossRefPubMedGoogle Scholar
  400. Toyama K, Yonezawa A, Masuda S, Osawa R, Hosokawa M, Fujimoto S et al (2011) Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis. Brit J Pharmacol 166:1183–1191CrossRefGoogle Scholar
  401. Tsuda M, Terada T, Asaka J, Ueba M, Katsura T, Inui K (2007) Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1. Am J Physiol Renal Physiol 292:F593–F598CrossRefPubMedGoogle Scholar
  402. Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T et al (2009a) Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 329:185–191CrossRefPubMedGoogle Scholar
  403. Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K (2009b) Targeted disruption of the multidrug and toxin extrusion 1 (mate 1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 75:1280–1286CrossRefPubMedGoogle Scholar
  404. Tu M, Sun S, Wang K, Peng X, Wang R, Li L et al (2013) Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important role in its hepatotoxicity. Toxicology 311:225–230CrossRefGoogle Scholar
  405. Tu M, Li L, Lei H, Ma Z, Chen Z, Sun S et al (2014) Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity. Toxicology 322:34–42CrossRefPubMedGoogle Scholar
  406. Tyce GM (1990) Origin and metabolism of serotonin. J Cardiovasc Pharmacol 16(Suppl 3):S1–S7CrossRefPubMedGoogle Scholar
  407. Tzvetkov MV, Saadatmand AR, Lötsch J, Tegeder I, Stingl JC, Brockmöller J (2011) Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther 90:143–150CrossRefPubMedGoogle Scholar
  408. Tzvetkov MV, dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC et al (2013) Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol 86:666–678CrossRefGoogle Scholar
  409. Umamaheswaran G, Praveen RG, Damodaran SE, Das AK, Adithan C (2015) Influence of SLC22A1 rs 622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. Clin Exp Med 15:511–517CrossRefPubMedGoogle Scholar
  410. Urakami Y, Kimura N, Okuda M, Inui K (2004) Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 21:976–981CrossRefPubMedGoogle Scholar
  411. Uwai Y, Ida H, Tsuji Y, Katsura T, Inui K (2007) Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 24:811–815CrossRefGoogle Scholar
  412. Uwai Y, Honjo H, Iwamoto K (2012) Interaction and transport of kynurenic acid via human organic anion transporters hOAT1 and hOAT3. Pharmacol Res 65:254–260CrossRefPubMedGoogle Scholar
  413. Vallon V, Rieg T, Ahn SY, Wu W, Eraly SA, Nigam SK (2008a) Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol 294:F867–F873CrossRefPubMedGoogle Scholar
  414. Vallon V, Eraly SA, Wikoff WR, Rieg T, Kaler G, Truong DM et al (2008b) Organic anion t ransporter 3 contributes to the regulation of blood pressure. J Am Soc Nephrol 19:1732–1740CrossRefPubMedPubMedCentralGoogle Scholar
  415. van de Steeg E, Stránecký V, Hartmannová H, Nosková L, Hřebíček M, Wagenaar E et al (2012) Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrom by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 122:519–528CrossRefPubMedPubMedCentralGoogle Scholar
  416. Varma MV, Rotter CJ, Chupka J, Whalen KM, Duignan DB, Feng B et al (2011) pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm 8:1303–1313CrossRefPubMedGoogle Scholar
  417. Vavricka SR, Musch MW, Chang JE, Nakagawa Y, Phanvijhitsiri K, Waypa TS et al (2004) hPepT1 transports muramyl dipeptide, activating NF-kappa B and stimulating IL-8 secretion in human colonic Caco 2/bbe cells. Gastroenterology 127:1401–1409CrossRefPubMedGoogle Scholar
  418. Vavricka SR, Musch MW, Fujiya M, Kles K, Chang L, Eloranta JJ et al (2006) Tumor necrosis factor-alpha and interferon-gamma increase Pep T1 expression and activity in the human colon carcinoma cell line Caco-2/bbe and in mouse intestine. Pflugers Arch 452:71–80CrossRefGoogle Scholar
  419. Vialou V, Balasse L, Callebert J, Launay JM, Giros B, Gautron S (2008) Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. J Neurochem 106:1471–1482PubMedGoogle Scholar
  420. Viennois E, Ingersoll SA, Ayyadurai S, Zhao Y, Wang L, Zhang M et al (2016) Critical role of PEPT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PEPT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol 2:340–357CrossRefPubMedPubMedCentralGoogle Scholar
  421. Vildhede A, Karlgren M, Svedberg EK, Wisniewski JR, Lai Y, Norén A et al (2014) Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. Drug Metab Dispos 42:1210–1218CrossRefPubMedGoogle Scholar
  422. Visentin M, Chang MH, Romero MF, Zhao R, Goldman ID (2012) Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1). Mol Pharmacol 81:134–142CrossRefPubMedPubMedCentralGoogle Scholar
  423. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA et al (2009) The SLCO1B1∗5 genetic variant is associated with statin induced side effects. J Am Coll Cardiol 54:1609–1616CrossRefPubMedPubMedCentralGoogle Scholar
  424. Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y (2003) Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 63:844–848CrossRefPubMedGoogle Scholar
  425. Wang X, Wolkoff AW, Morris ME (2005) Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 33:1666–1672CrossRefPubMedGoogle Scholar
  426. Wang ZJ, Yin OQ, Tomlinson B, Chow MS (2008) OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 18:637–645CrossRefPubMedGoogle Scholar
  427. Wang C, Uray IP, Mazumdar A, Mayer JA, Brown PH (2012) SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE). Breast Cancer Res Treat 134:101–115CrossRefPubMedPubMedCentralGoogle Scholar
  428. Wang L, Wang C, Liu Q, Meng Q, Huo X, Sun P et al (2014) PEPT1- and OAT1/3-mediated drug-drug interactions between bestatin and cefixime in vivo and in vitro in rats, and in vitro in human. Eur J Pharm Sci 63:77–86CrossRefPubMedGoogle Scholar
  429. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z et al (2010a) Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38:215–222CrossRefPubMedGoogle Scholar
  430. Watanabe S, Tsuda M, Terada T, Katsura T, Inui K (2010b) Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther 334:651–656CrossRefPubMedGoogle Scholar
  431. Weaver YM, Hagenbuch B (2010) Several conserved positively charged amino acids in OATP1B1 are involved in binding or translocation of different substrates. J Membr Biol 236:279–290CrossRefPubMedPubMedCentralGoogle Scholar
  432. Weleber RG, Shults WT (1981) Digoxin retinal toxicity. Clinical and electrophysiological evaluation of a cone dysfunction syndrome. Arch Ophthalmol 99:1568–1572CrossRefGoogle Scholar
  433. White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S et al (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:4064–4072CrossRefPubMedGoogle Scholar
  434. Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X et al (2013) Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem 56:781–795CrossRefPubMedPubMedCentralGoogle Scholar
  435. Wu SP, Smith DE (2013) Impact of intestinal Pep T1 on the kinetics and dynamics of N-formyl-methionyl-leucyl-phenylalanine, a bacterially-produced chemotactic peptide. Mol Pharm 10:677–684CrossRefPubMedGoogle Scholar
  436. Wu W, Dnyanmote AV, Nigam SK (2011) Remote communication through solute carriers and ATP binding cassette drug transporter pathways: an update on the remote sensing and signaling hypothesis. Mol Pharmacol 79:795–805CrossRefPubMedPubMedCentralGoogle Scholar
  437. Wu W, Jamshidi N, Eraly SA, Liu HC, Bush KT, Palsson BO et al (2013) Multispecific drug transporter Slc 22a8 (Oat 3) regulates multiple metabolic and signaling pathways. Drug Metab Dispos 41:1825–1834CrossRefPubMedPubMedCentralGoogle Scholar
  438. Wu KC, Lu YH, Peng YH, Tsai TF, Kao YH, Yang HT, Lin CJ (2015a) Decreased expression of organic cation transporters, Oct 1 and Oct 2, in brain microvessels and its implication to MPTP-induced dopaminergic toxicity in aged mice. J Cereb Blood Flow Metab 35:37–47CrossRefPubMedPubMedCentralGoogle Scholar
  439. Wu X, Zhang J, Liu H, Mian Y, Liang B, Xie H et al (2015b) Organic anion transporter 1 deficiency accelerates learning and memory impairment in tg 2576 mice by damaging dendritic spine morphology and activity. J Mol Neurosci 56:730–738CrossRefPubMedGoogle Scholar
  440. Wuensch T, Schulz S, Ullrich S, Lill N, Stelzl T, Rubio-Aliaga I et al (2013) The peptide transporter PEPT1 is expressed in distal colon in rodents and humans and contributes, to water absorption. Am J Physiol Gastrointest Liver Physiol 305:G66–G73CrossRefPubMedGoogle Scholar
  441. Wuensch T, Ullrich S, Schulz S, Chamaillard M, Schaltenberg N, Rath E et al (2014) Colonic expression of the peptide transporter PEPT1 is downregulated during intestinal inflammation and is not required for NOD2-dependent immune activation. Inflamm Bowel Dis 20:671–684CrossRefPubMedGoogle Scholar
  442. Wultsch T, Grimberg G, Schmitt A, Painsipp E, Wetzstein H, Breitenkamp AF (2009) Decreased anxiety in mice lacking the organic cation transporter 3. J Neural Transm (Vienna) 116:689–697CrossRefGoogle Scholar
  443. Xiao D, Guo Y, Li X, Yin JY, Zheng W, Qiu XW et al (2016) The impacts of SLC22A1 rs 594709 and SLC47A1 rs 2289669 polymorphisms on metformin therapeutic efficacy in Chinese type 2 diabetes patients. Int J Endocrinol 2016:4350712PubMedPubMedCentralGoogle Scholar
  444. Xu D, Zhang J, Zhang M, Mei D, Liu XD (2013) Pharmacokinetics roles of organic transporting polypeptides. J Chin Pharmacet Uni 44:482–486Google Scholar
  445. Xu D, Li F, Zhang M, Zhang J, Liu C, Hu MY et al (2014) Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes. Acta Pharmacol Sin 35:1215–1225CrossRefPubMedPubMedCentralGoogle Scholar
  446. Xu C, Zhu L, Chan T, Lu X, Shen W, Madigan MC et al (2016) Chloroquine and hydroxychloroquine are novel inhibitors of human organic anion transporting polypeptide 1A2. J Pharm Sci 105:884–890CrossRefGoogle Scholar
  447. Xue X, Gong LK, Maeda K, Luan Y, Qi XM, Sugiyama Y et al (2011) Critical role of organic anion transporters 1 and 3 in kidney accumulation and toxicity of aristolochic acid I. Mol Pharm 8:2183–2192CrossRefGoogle Scholar
  448. Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y et al (2007) Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos 35:2166–2176CrossRefGoogle Scholar
  449. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y (2006) Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34:1247–1254CrossRefGoogle Scholar
  450. Yan Z, Sun J, Chang Y, Liu Y, Fu Q, Xu Y et al (2011) Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics. Mol Pharm 8:319–329CrossRefPubMedGoogle Scholar
  451. Yang B, Smith DE (2013) Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PEPT1 knockout mice. Drug Metab Dispos 41:608–614CrossRefPubMedPubMedCentralGoogle Scholar
  452. Yang B, Hu Y, Smith DE (2013) Impact of Peptide Transporter 1 on the intestinal absorption and pharmacokinetics of valacyclovir after oral dose escalation in wild-type and PEPT1 knockout mice. Drug Metab Dispos 41:1867–1874CrossRefPubMedPubMedCentralGoogle Scholar
  453. Yang H, Guo D, Obianom ON, Su T, Polli JE, Shu Y (2017) Multidrug and toxin extrusion proteins mediate cellular transport of cadmium. Toxicol Appl Pharmacol 314:55–62CrossRefPubMedGoogle Scholar
  454. Yaylali SA, Sadigov F, Erbil H, Ekinci A, Akcakaya AA (2013) Chloroquine and hydroxychloroquine retinopathy-related risk factors in a Turkish cohort. Int Ophthalmol 33:627–634CrossRefGoogle Scholar
  455. Ye J, Liu Q, Wang C, Meng Q, Sun H, Peng J, Ma X, Liu K (2013) Benzylpenicillin inhibits the renal excretion of acyclovir by OAT1 and OAT3. Pharmacol Rep 65:505–512CrossRefPubMedGoogle Scholar
  456. Yeh YC, Huang MF, Liang SS, Hwang SJ, Tsai JC, Liu TL et al (2016) Indoxyl sulfate, not p-cresyl sulfate, is associated with cognitive impairment in early-stage chronic kidney disease. Neurotoxicology 53:148–152CrossRefPubMedGoogle Scholar
  457. Yin OQ, Tomlinson B, Chow MS (2006) Variability in renal clearance of substrates for renal transporters in Chinese subjects. J Clin Pharmacol 46:157–163CrossRefPubMedGoogle Scholar
  458. Yin J, Duan H, Shirasaka Y, Prasad B, Wang J (2015) Atenolol renal secretion is mediated by human organic cation transporter 2 and multidrug and toxin extrusion proteins. Drug Metab Dispos 43:1872–1881CrossRefPubMedPubMedCentralGoogle Scholar
  459. Yin J, Duan H, Wang J (2016) Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation. J Pharmacol Exp Ther 359:401–410CrossRefPubMedPubMedCentralGoogle Scholar
  460. Yokoo S, Yonezawa A, Masuda S, i Fukatsu A, Katsura T, Inui KI (2007) Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharamcol 74:477–487CrossRefGoogle Scholar
  461. Yonezawa A, Inui K (2011) Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Brit J Pharmacol 164:1817–1825CrossRefGoogle Scholar
  462. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K (2006) Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319:879–886CrossRefGoogle Scholar
  463. Zaïr ZM, Eloranta JJ, Stieger B, Kullak-Ublick GA (2008) Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 9:597–624CrossRefPubMedGoogle Scholar
  464. Zhang J, Zhou W (2012) Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol 50:2289–2293CrossRefGoogle Scholar
  465. Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD et al (2007) SLCOB1 521T>C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol 64:346–352CrossRefPubMedPubMedCentralGoogle Scholar
  466. Zhang Y, Sun J, Gao Y, Jin L, Xu Y, Lian H et al (2013) A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine. Mol Pharm 10:3195–3202CrossRefPubMedGoogle Scholar
  467. Zhang Y, Warren MS, Zhang X, Diamond S, Williams B, Punwani N et al (2015) Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110. Drug Metab Dispos 43:485–489CrossRefPubMedGoogle Scholar
  468. Zhou Q, Liao JK (2010) Pleiotropic effects of statins: basic research and clinical perspectives. Circ J 74:818–826CrossRefPubMedPubMedCentralGoogle Scholar
  469. Zhou Y, Yuan J, Li Z, Wang Z, Cheng D, Du Y et al (2015) Genetic polymorphisms and function of the organic anion-transporting polypeptide 1A2 and its clinical relevance in drug disposition. Pharmacology 95:201–208CrossRefPubMedGoogle Scholar
  470. Zhou F, Zhu L, Wang K, Murray M (2017) Recent advance in the pharmacogenomics of human solute carrier 2 transporters (SLCs) in drug disposition. Adv Drug Deliv Rev 116:21–36CrossRefPubMedGoogle Scholar
  471. Zhu HJ, Appela DI, Gründemannc D, Richelsond E, Markowitz JS (2012) Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action. Pharmacol Res 65:491–496CrossRefPubMedPubMedCentralGoogle Scholar
  472. Ziegler TR, Fernandez-Estivariz C, Gu LH, Bazargan N, Umeakunne K, Wallace TM et al (2002) Distribution of the H+/peptide transporter PEPT1 in human intestine: upregulated expression in the colonic mucosa of patients with short-bowel syndrome. Am J Clin Nutr 75:922–930CrossRefPubMedPubMedCentralGoogle Scholar
  473. Zimmerman EL, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L et al (2013) Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 19:1458–1466CrossRefPubMedPubMedCentralGoogle Scholar
  474. Zolk O, Solbach TF, König J, Fromm MF (2009) Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos 37:1312–1318CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.China Pharmaceutical UniversityNanjingChina

Personalised recommendations